NCT04696822 - Bioavailability of Nasal Epinephrine | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 1, 2020

Primary Completion Date

September 28, 2021

Study Completion Date

September 28, 2021

Conditions

Anaphylaxis

Interventions

DRUG

Epinephrine Nasal Product, 1.6 mg

Single dose Nasal powder spray without allergen challenge

DRUG

Epinephrine nasal product, 1.6 mg + allergen

Single dose Nasal powder spray with allergen challenge

DRUG

Epinephrine Injection 0.3 mg

Intramuscular injection

DRUG

Epinephrine Nasal Product, 3.2 mg

Twice dose Nasal powder spray without allergen challenge

DRUG

Epinephrine Nasal Product, 3.2 mg + allergen

Twice dose Nasal powder spray with allergen challenge

Trial Locations (1)

Hadassah Medical Center, Ein Kerem, Jerusalem